Table 4.
Quality of life in men with prostate cancer
| Study (year) | Health state | Mean (SD or 95% CI) utility value | |||||
|---|---|---|---|---|---|---|---|
| EQ-5D | EORTC-8D | PORPUS-U | HUI-2 | HUI-3 | QWB | ||
| France | |||||||
| Sullivan et al. (2007) [54] | Metastatic hormone refractory prostate cancer, baseline | 0.669 | |||||
| Germany | |||||||
| Sullivan et al. (2007) [54] | Metastatic hormone refractory prostate cancer, baseline | 0.527 | |||||
| UK | |||||||
| Sullivan et al. (2007) [54] | Metastatic hormone refractory prostate cancer, baseline | 0.715 | |||||
| Hall et al. (2015) [45] | Baseline, at diagnosis | 0.838 | |||||
| 9 months post-diagnosis | 0.868 | ||||||
| 15 months post-diagnosis | 0.868 | ||||||
| Lloyd et al. (2015) [55] | MCRPC asymptomatic/mildly symptomatic before chemotherapy | 0.830 (0.126) | 0.856 (0.089) | ||||
| MCRPC symptomatic before chemotherapy | 0.625 (0.173) | 0.697 (0.118) | |||||
| MCRPC currently receiving chemotherapy | 0.692 (0.219) | 0.750 (0.117) | |||||
| MCRPC post chemotherapy | 0.700 (0.183) | 0.753 (0.133) | |||||
| Watson et al. (2016) [56] | Diagnosed with prostate cancer in previous 9–24 months (overall) | 0.852 (0.173) | |||||
| No moderate/big problem with urine function | 0.868 (0.160) | ||||||
| No moderate/big problem with bowel function | 0.862 (0.166) | ||||||
| No moderate/big problem with sexual function | 0.861 (0.176) | ||||||
| Moderate/big problem with urine function | 0.773 (0.222) | ||||||
| Moderate/big problem with bowel function | 0.653 (0.195) | ||||||
| Moderate/big problem with sexual function | 0.838 (0.170) | ||||||
| Canada | |||||||
| Krahn et al. (2013) [57] | Prostate cancer survivors (overall) | 0.91 (0.08) | 0.85 (0.15) | 0.78 (0.24) | |||
| Krahn et al. (2007) [58] | Localized prostate cancer receiving radical prostatectomy, radiation, or hormonal therapy | 0.84 | 0.87 | 0.81 | 0.61 | ||
| Metastatic disease | 0.84 | 0.86 | 0.82 | 0.63 | |||
| Stable patients | 0.85 | 0.86 | 0.81 | 0.63 | |||
| Ku et al. (2009) [59] | Patients undergoing radical prostatectomy, baseline (pre-surgery) | 0.94 (0.93–0.95) | |||||
| Patients undergoing radical prostatectomy, 0–3 months post surgery | 0.81 (0.79–0.82) | ||||||
| Patients undergoing radical prostatectomy, 3–9 months post surgery | 0.87 (0.86–0.89) | ||||||
| Patients undergoing radical prostatectomy, 9–18 months post surgery | 0.89 (0.87–0.90) | ||||||
| Patients undergoing radical prostatectomy, 18–30 months post surgery | 0.90 (0.88–0.91) | ||||||
| Sullivan et al. (2007) [54] | Metastatic hormone refractory prostate cancer, baseline | 0.750 | |||||
| Gries et al. (2016) [60] | Men at risk for prostate cancer | 0.83 (0.168) | 0.77 (0.238) | ||||
| Men with prostate cancer | 0.83 (0–124) | 0.75 (0.260) | |||||
| General population | 0.87 (0.136) | 0.84 (0.178) | |||||
| Bremner et al. (2007) [61] | Men with prostate cancer (overall population) | 0.80 (0.19) | 0.65 (0.13) | ||||
MCRPC metastatic hormone resistant prostate cancer